Germany’s generics and OTCs manufacturer Stada has announced this week its second quarter financial results. Revenues kept the Q2 2017 level and were up 6% at constant exchange rates, while EBITDA increased by 26% to €142m. The group CEO Claudio Albrecht has said at the telephone conference call to investors that the cost cut plan is proceeding according to schedule. The only negative is perhaps that the Branded Products division has reported a $5m revenues increase–to €233m–but also a 12% EBITDA decline. On the contrary, sales from the Generics division have decreased (-1% in revenues), but profit has increased by 23%.